Mathavan Akash, Mathavan Akshay, Krekora Urszula, Rao Adityanarayan, Zumberg Marc S, Justice Jeb, Bayrak-Toydemir Pinar, McDonald Jamie, Ataya Ali
Department of Internal Medicine, University of Florida, Gainesville, FL, United States.
College of Medicine, University of Florida, Gainesville, FL, United States.
Front Genet. 2025 Mar 14;16:1554624. doi: 10.3389/fgene.2025.1554624. eCollection 2025.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder caused by pathogenic variants in genes within the transforming growth factor beta (TGF-β) signaling pathway, such as , leading to haploinsufficiency. Homozygous variants in HHT-related genes are exceptionally rare and have not been reported in -related HHT to date. We report the first known instance of a novel homozygous missense variant in the gene (c.576C>G; p.Phe192Leu) identified in two siblings from a family of seven, in which three heterozygotes were also present. Comprehensive clinical evaluations revealed striking phenotypic differences between the homozygous and heterozygous family members. Both homozygous individuals exhibited early-onset pulmonary arterial hypertension and diffuse pulmonary arteriovenous malformations. One of them also demonstrated childhood-onset gastrointestinal bleeding-a manifestation unprecedented in HHT that typically has a late-adulthood onset. In contrast, the heterozygotes displayed either mild or equivocal features of HHT, supporting the classification of this variant as a hypomorphic allele. The novel missense variant is located within the intracellular glycine-serine (GS) domain of the protein, suggesting potential impacts on receptor regulation and downstream signaling. Although these findings expand the phenotypic spectrum of -related HHT, they remain limited to clinical observations. Experimental studies, including functional and molecular assays, are therefore essential to confirm the pathogenic impacts of this variant, validate its classification as a hypomorphic allele, and elucidate its effects on BMP-TGF-β signaling.
遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性血管疾病,由转化生长因子β(TGF-β)信号通路中的基因致病性变异引起,例如 ,导致单倍剂量不足。HHT相关基因的纯合变异极为罕见,迄今为止在与 相关的HHT中尚未有报道。我们报告了在一个七口之家的两名兄弟姐妹中发现的 基因中一种新型纯合错义变异(c.576C>G;p.Phe192Leu)的首个已知实例,该家庭中还存在三名杂合子。全面的临床评估揭示了纯合子和杂合子家庭成员之间显著的表型差异。两名纯合个体均表现出早发性肺动脉高压和弥漫性肺动静脉畸形。其中一人还出现了儿童期胃肠道出血——这是HHT中前所未有的表现,通常在成年后期发病。相比之下,杂合子表现出HHT的轻度或不明确特征,支持将该变异分类为亚效等位基因。这种新型错义变异位于该蛋白的细胞内甘氨酸 - 丝氨酸(GS)结构域内,提示对受体调节和下游信号传导可能产生影响。尽管这些发现扩展了与 相关的HHT的表型谱,但仍仅限于临床观察。因此,包括功能和分子检测在内的实验研究对于确认该变异的致病影响、验证其作为亚效等位基因的分类以及阐明其对骨形态发生蛋白 - TGF-β信号传导的影响至关重要。